A 2025 review highlighted its approval by both the FDA and the Australian TGA for patients aged 12 years and older with WHO grade 2 gliomas (IDH1 or IDH2 mutant), reaffirming its PFS benefit (27.7 months vs. 11.1 months) and good tolerability in children and adolescents, with grade 3 or higher adverse events like transaminase elevation occurring in less than 50% of cases (40). Here, IDH2 is linked to central nervous system cancer.